Effect of different administration methods of esketamine on postoperative depression in patients undergoing heart valve replacement
Objective To investigate the impact of single or continuous administration of subanesthetic doses of eske-tamine during anesthesia on postoperative depression in patients undergoing heart valve replacement. Methods A total of 256 patients who underwent heart valve replacement in our hospital from Au...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of Precision Medicine
2025-06-01
|
| Series: | 精准医学杂志 |
| Subjects: | |
| Online Access: | https://jpmed.qdu.edu.cn/fileup/2096-529X/PDF/1750385760892-1572916038.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objective To investigate the impact of single or continuous administration of subanesthetic doses of eske-tamine during anesthesia on postoperative depression in patients undergoing heart valve replacement. Methods A total of 256 patients who underwent heart valve replacement in our hospital from August 2023 to August 2024 were enrolled, and according to the use of esketamine during surgery, the patients were divided into control group (group C), single-dose group (group S-S), and continuous-dose group (group C-S). General information was collected and compared between the three groups, as well as 17-item Hamilton Depression Rating Scale (HAMD-17) score and the constituent ratio of patients with depressed mood on day 1 before surgery and on days 3, 7, and 30 after surgery, Visual Analog Scale (VAS) pain score and Self-Rating Scale of Sleep (SRSS) score on day 3 after surgery, and the incidence rate of adverse reactions within 1 week after surgery. Results Group C-S had a significantly lower VAS score than group C on day 3 after surgery (F=4.617,P<0.05). The three groups showed a significant change in HAMD-17 score from before surgery to different time points after surgery (Fintragroup=4.497-18.254,P<0.05); in group C, HAMD-17 score on day 3 after surgery was significantly higher than that on day 1 before surgery (P<0.01), while in group C-S, HAMD-17 score on day 7 after surgery was significantly higher than that on day 1 before surgery (P<0.05); for all three groups, HAMD-17 score at 1 month after surgery was significantly lower than that on day 1 before surgery (P<0.05). There were significant diffe-rences in HAMD-17 score between the three groups on days 3 and 7 after surgery (Fintergroup=7.218,7.809,P<0.05); groups C-S and S-S had a significantly lower HAMD-17 score than group C on day 3 after surgery (P<0.05), while group C-S had a significantly lower HAMD-17 score than group C on day 7 after surgery (P<0.05). For group C, the constituent ratio of patients who deve-loped depressed mood on day 3 after surgery was significantly higher than that on day 1 before surgery (Wald χ2=33.704,P<0.01), and there was no significant change in the constituent ratio of patients who developed depressed mood after surgery in the other two groups (P>0.05). Conclusion Continuous intrao-perative application of subanesthetic doses of esketamine can improve depressive symptoms within a short period of time after surgery and alleviate postoperative pain in patients undergoing heart valve replacement, without increasing the incidence rate of adverse reactions. This approach can help to promote the postoperative recovery of patients undergoing heart valve replacement. |
|---|---|
| ISSN: | 2096-529X |